Investor Relations

Voluntary Announcement Submission of Application for New Drug Clinical Trial Communication Meeting RC19D2

Release time：2022-02-03 18:16

CW06978ann0203

File size: 216.1KB

Select all

(Revised) Monthly report on the changes in securities of the issuer of shares for the month ended December 31, 2021.

The first patient has been enrolled in the Phase I clinical trial of the voluntary announcement 6B11-OCIK injection.

(Revised) Monthly report on the changes in securities of the issuer of shares for the month ended December 31, 2021.

The first patient has been enrolled in the Phase I clinical trial of the voluntary announcement 6B11-OCIK injection.

+86-10-88400295

www.eaal.net

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business License